Please login to the form below

Not currently logged in
Email:
Password:

Namenda

This page shows the latest Namenda news and features for those working in and with pharma, biotech and healthcare.

Forest said to be interested in $3bn Aptalis acquisition

Forest said to be interested in $3bn Aptalis acquisition

US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine). ... With Lexapro and Namenda accounting for more than three quarters of company turnover at

Latest news

  • Lundbeck and Otsuka take Alzheimer's drug into phase III Lundbeck and Otsuka take Alzheimer's drug into phase III

    Regardless, it has been 10 years since the last new Alzheimer's treatment reached the market - Lundbeck's glutamate (NMDA) antagonist Ebixa (memantine), which is sold as Namenda by Forest Labs

  • Forest's net income down for Q3

    He said: "We have been working diligently for the past seven years to build a solid product development pipeline that will more than replace the loss of Lexapro and Namenda following

  • Forest Laboratories earnings rise

    Lexapro (escitalopram) and its Alzheimer's drug Namenda (memantine) lose their patent protection in the coming years. . ... expiration for both Lexapro in 2012 and Namenda in 2015 and provide growth," he said.

  • Lifting the fog

    Additionally, a patch formulation of donepezil is in development. Also approved for the treatment of moderate-to-severe AD is memantine (Namenda, Forest Laboratories), which was the first NMDA receptor antagonist

  • Forest Labs earnings fall in Q2

    revenues lost due to patent expiration for Lexapro in 2012 and [the Alzheimer's drug] Namenda (memantine) in 2015.".

More from news
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics